State of Alaska Department of Revenue grew its position in Organon & Co. (NYSE:OGN - Free Report) by 417.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,249 shares of the company's stock after acquiring an additional 126,882 shares during the quarter. State of Alaska Department of Revenue owned 0.06% of Organon & Co. worth $2,267,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently modified their holdings of the company. Quilter Plc purchased a new position in shares of Organon & Co. in the 1st quarter worth approximately $854,973,000. Wellington Shields Capital Management LLC purchased a new position in shares of Organon & Co. in the 4th quarter worth approximately $27,000. Harvest Fund Management Co. Ltd boosted its holdings in shares of Organon & Co. by 495.5% in the 3rd quarter. Harvest Fund Management Co. Ltd now owns 1,602 shares of the company's stock worth $28,000 after purchasing an additional 1,333 shares during the period. Harbour Investments Inc. boosted its holdings in shares of Organon & Co. by 93.3% in the 2nd quarter. Harbour Investments Inc. now owns 1,976 shares of the company's stock worth $41,000 after purchasing an additional 954 shares during the period. Finally, Headlands Technologies LLC purchased a new position in shares of Organon & Co. in the 3rd quarter worth approximately $35,000. Hedge funds and other institutional investors own 77.43% of the company's stock.
Organon & Co. Stock Down 0.1 %
OGN traded down $0.01 during trading hours on Friday, reaching $17.86. 2,010,061 shares of the company's stock traded hands, compared to its average volume of 2,825,355. The firm has a market capitalization of $4.57 billion, a PE ratio of 4.47, a PEG ratio of 0.85 and a beta of 0.83. The firm has a 50-day moving average price of $17.76 and a 200 day moving average price of $15.62. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $24.79.
Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Thursday, February 15th. The company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.73 by $0.14. The business had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a net margin of 16.33% and a negative return on equity of 212.00%. Equities analysts predict that Organon & Co. will post 4.08 EPS for the current fiscal year.
Organon & Co. Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were issued a $0.28 dividend. The ex-dividend date was Friday, February 23rd. This represents a $1.12 annualized dividend and a dividend yield of 6.27%. Organon & Co.'s dividend payout ratio (DPR) is presently 28.00%.
Insider Transactions at Organon & Co.
In other news, insider Kirke Weaver acquired 2,720 shares of the company's stock in a transaction dated Thursday, February 22nd. The shares were acquired at an average price of $18.36 per share, with a total value of $49,939.20. Following the purchase, the insider now directly owns 15,181 shares of the company's stock, valued at $278,723.16. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 1.17% of the company's stock.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group lifted their target price on Organon & Co. from $16.00 to $18.00 and gave the stock a "neutral" rating in a report on Tuesday, February 20th.
Check Out Our Latest Analysis on Organon & Co.
Organon & Co. Profile
(
Free Report)
Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.
Read More
Before you consider Organon & Co., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organon & Co. wasn't on the list.
While Organon & Co. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
